Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment

Feng Ming Hsu, Shichuan Zhang, Benjamin P C Chen

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a key component of the non-homologous end-joining (NHEJ) pathway, is involved in DNA double-strand break repair, immunocompetence, genomic integrity, and epidermal growth factor receptor signaling. Clinical studies indicate that expression and activity of DNA-PKcs is correlated with cancer progression and response to treatment. Various anti-DNA-PKcs strategies have been developed and tested in preclinical studies to exploit the benefit of DNA-PKcs inhibition in sensitization of radiotherapy and in combined modality therapy with other antitumor agents. In this article, we review the association between DNA-PKcs and cancer development and discuss current approaches and mechanisms for inhibition of DNA-PKcs. The future challenges are to understand how DNA-PKcs activity is correlated with cancer susceptibility and to identify those patients who would most benefit from DNA-PKcs inhibition.

Original languageEnglish (US)
Pages (from-to)22-34
Number of pages13
JournalTranslational Cancer Research
Volume1
Issue number1
DOIs
StatePublished - Jun 1 2012

Fingerprint

DNA-Activated Protein Kinase
Catalytic Domain
Neoplasms
Therapeutics
Immunocompetence
Combined Modality Therapy
Double-Stranded DNA Breaks
Epidermal Growth Factor Receptor
Antineoplastic Agents
Radiotherapy

Keywords

  • Anti-DNA-PKcs strategies
  • Carcinogenesis
  • DNA damage

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment. / Hsu, Feng Ming; Zhang, Shichuan; Chen, Benjamin P C.

In: Translational Cancer Research, Vol. 1, No. 1, 01.06.2012, p. 22-34.

Research output: Contribution to journalArticle

@article{e2637973eb3349568f793633d4fa599d,
title = "Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment",
abstract = "DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a key component of the non-homologous end-joining (NHEJ) pathway, is involved in DNA double-strand break repair, immunocompetence, genomic integrity, and epidermal growth factor receptor signaling. Clinical studies indicate that expression and activity of DNA-PKcs is correlated with cancer progression and response to treatment. Various anti-DNA-PKcs strategies have been developed and tested in preclinical studies to exploit the benefit of DNA-PKcs inhibition in sensitization of radiotherapy and in combined modality therapy with other antitumor agents. In this article, we review the association between DNA-PKcs and cancer development and discuss current approaches and mechanisms for inhibition of DNA-PKcs. The future challenges are to understand how DNA-PKcs activity is correlated with cancer susceptibility and to identify those patients who would most benefit from DNA-PKcs inhibition.",
keywords = "Anti-DNA-PKcs strategies, Carcinogenesis, DNA damage",
author = "Hsu, {Feng Ming} and Shichuan Zhang and Chen, {Benjamin P C}",
year = "2012",
month = "6",
day = "1",
doi = "10.3978/j.issn.2218-676X.2012.04.01",
language = "English (US)",
volume = "1",
pages = "22--34",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",
number = "1",

}

TY - JOUR

T1 - Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment

AU - Hsu, Feng Ming

AU - Zhang, Shichuan

AU - Chen, Benjamin P C

PY - 2012/6/1

Y1 - 2012/6/1

N2 - DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a key component of the non-homologous end-joining (NHEJ) pathway, is involved in DNA double-strand break repair, immunocompetence, genomic integrity, and epidermal growth factor receptor signaling. Clinical studies indicate that expression and activity of DNA-PKcs is correlated with cancer progression and response to treatment. Various anti-DNA-PKcs strategies have been developed and tested in preclinical studies to exploit the benefit of DNA-PKcs inhibition in sensitization of radiotherapy and in combined modality therapy with other antitumor agents. In this article, we review the association between DNA-PKcs and cancer development and discuss current approaches and mechanisms for inhibition of DNA-PKcs. The future challenges are to understand how DNA-PKcs activity is correlated with cancer susceptibility and to identify those patients who would most benefit from DNA-PKcs inhibition.

AB - DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a key component of the non-homologous end-joining (NHEJ) pathway, is involved in DNA double-strand break repair, immunocompetence, genomic integrity, and epidermal growth factor receptor signaling. Clinical studies indicate that expression and activity of DNA-PKcs is correlated with cancer progression and response to treatment. Various anti-DNA-PKcs strategies have been developed and tested in preclinical studies to exploit the benefit of DNA-PKcs inhibition in sensitization of radiotherapy and in combined modality therapy with other antitumor agents. In this article, we review the association between DNA-PKcs and cancer development and discuss current approaches and mechanisms for inhibition of DNA-PKcs. The future challenges are to understand how DNA-PKcs activity is correlated with cancer susceptibility and to identify those patients who would most benefit from DNA-PKcs inhibition.

KW - Anti-DNA-PKcs strategies

KW - Carcinogenesis

KW - DNA damage

UR - http://www.scopus.com/inward/record.url?scp=84962662283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962662283&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2218-676X.2012.04.01

DO - 10.3978/j.issn.2218-676X.2012.04.01

M3 - Article

VL - 1

SP - 22

EP - 34

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

IS - 1

ER -